The COVID-19 vaccine research and development conducted by Oxford University together with AstraZeneca made a major breakthrough today.
- Oxford University in partnership with AstraZeneca produces the ChAdOx1 nCoV-19 vaccine
- The vaccine produces antibodies and killer T-cells
- Neutralizing antibodies detected in participants even after 28 days
What were they testing for?
They were testing for two things- the proof of concept, and whether there are any side effects.
What were the results?
A potential coronavirus vaccine developed by Oxford University in the U.K. with pharmaceutical giant AstraZeneca has produced a strong immune response in a large and was named as ChAdOx1 nCoV-19
The reseachers said the vaccine produced both antibodies and Killer T-cells to combat the infection.Neutralizing antibodies, which would play a crucial role in protecting against the virus were detected in participants after 28 days. This is a promising step towards the development of the vaccine as it would provide protection to a human for an extended period.
The immune system has two methods of finding and attacking pathegons. They are ;
- T-cell responses
The team at Oxford continues to develop the COVID-19 vaccine by focusing on the above two factors. Oxford professor Andrew Pollard said in a release. “This vaccine is intended to induce both, so it can attack the virus when it’s circulating in the body, as well as attacking infected cells. We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period”
It was also established that the vaccine would be well tolerated and there were no serious adverse reactions observed by the researchers in the participants. Nevertheless, fatigue and headache were the most commonly reported. Other side effects included pain at the injection site, muscle ache, chills, and a fever.
Professor Adrian Hill, director of Oxford University’s Jenner Institute, illustrated that the resounding immune response means the vaccine is more likely to provide protection against the virus, though nothing is certain. It was also highlighted that there are hoping to begin human trials in the United States in the next few weeks. Furthermore, the blood samples tested showed that the response would be different with the doses.
What conclusions can we draw?
One could consider the results to be promising. As they proved the concept. The results show that when the vaccine is given, the body develops antibodies. However, we don’t know whether the antibodies would lead to immunity from the Corona virus
Despite the encouraging results the scientists hope the antibodies provide some degree of protection against contracting Covid-19, but they can’t say that definitively yet since the virus was discovered just six months ago.
In spite of the positive results one might conclude that there is a long way to go in developing it to something that is capable of being used in a much larger scale.